AP
DGX icon

Arlington Partners’s Quest Diagnostics DGX Stock Holding History

Arlington Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11
Closed -$1.34K – 263
2023
Q3 		$1.34K Hold
11
– – ﹤0.01% 291
2023
Q2 		$1.55K Hold
11
– – ﹤0.01% 548
2023
Q1 		$1.56K Buy
+11
New +$1.57K ﹤0.01% 516
2022
Q1 		– Sell
-61
Closed -$11K – 499
2021
Q4 		$11K Buy
+61
New +$9.28K ﹤0.01% 455

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arlington Partners's DGX Position: Q4 2023 in Review

Arlington Partners sold out of Quest Diagnostics (DGX) in Q4 2023, closing a stake of 11 shares — an estimated $1.34K sold.

Arlington Partners first reported a position in DGX in Q4 2021 and held it in 4 quarters. The position peaked at $11K in Q4 2021. 827 funds tracked by Wall St. Rank hold DGX as of Q4 2023.

  • Arlington Partners reported no remaining Quest Diagnostics position as of Q4 2023 after selling out during the quarter.
  • Arlington Partners sold 11 Quest Diagnostics shares in Q4 2023, an estimated $1.34K.
  • Arlington Partners first reported a position in Quest Diagnostics in Q4 2021 and held it in 4 quarters.
  • Arlington Partners's Quest Diagnostics position peaked at $11K in Q4 2021.
  • 827 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2023.

Based on Arlington Partners's 13F filing for Q4 2023, filed 24 Jan 2024.